Drug Trial Radar · NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jan 16, 2026
Primary completion
Feb 26, 2032
Study completion Sep 2, 2036
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active surveillance, based on local practice guidelines. The main purpose of the study is to determine whether zongertinib can prolong disease-free survival compared to standard treatment. Safety and patient-reported outcomes are also assessed.
Conditions
- Non-small Cell Lung Cancer
Interventions
ZongertinibDrug
Zongertinib
PembrolizumabDrug
Pembrolizumab
AtezolizumabDrug
Atezolizumab
DurvalumabDrug
Durvalumab
NivolumabDrug
Nivolumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survival (DFS) by investigator's assessmentTime frame: up to 8 years and 5 months
Locations
205 sites in 28 countries. Site status is shown where the registry gives one.
ClinRé 001-022 (Premier Cancer Care and Infusion Center)
Fresno, California · Recruiting
OPN Healthcare, Inc.
Glendale, California · Recruiting
University of California Irvine
Orange, California · Recruiting
Sutter Health
Roseville, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Sarcoma Oncology Center
Santa Monica, California · Recruiting
University of California Los Angeles
Santa Monica, California · Recruiting
Northern California Kaiser Permanente
Vallejo, California · Not yet recruiting
George Washington University Cancer Center
Washington D.C., District of Columbia · Not yet recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida · Recruiting
Piedmont Cancer Institute
Atlanta, Georgia · Recruiting
Northwest Georgia Oncology Centers
Marietta, Georgia · Recruiting
Saint Alphonsus Regional Medical Center - Boise
Boise, Idaho · Not yet recruiting
Northwestern University
Chicago, Illinois · Not yet recruiting
University of Illinois Hospital and Health Sciences System
Chicago, Illinois · Recruiting
Duly Health and Care - Lisle
Lisle, Illinois · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Cancer Care Specialists
Reno, Nevada · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Durham VA Health Care System
Durham, North Carolina · Not yet recruiting
Levine Cancer Institute
Winston-Salem, North Carolina · Not yet recruiting
Providence Cancer Institute
Portland, Oregon · Recruiting
Hendrick Health
Abilene, Texas · Recruiting
Texas Oncology - Amarillo
Amarillo, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Community Cancer Trials of Utah
Ogden, Utah · Recruiting
Virginia Cancer Specialists, PC
Fairfax, Virginia · Recruiting
Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion)
CABA, Argentina · Recruiting
Hospital Britanico de Buenos Aires
CABA, Argentina · Recruiting
Centro Oncologico Korben
CABA, Argentina · Recruiting
Clinica Adventista Belgrano
CABA, Argentina · Recruiting
Instituto Medico Especializado Alexander Fleming
Ciudad Autónoma de Bs As, Argentina · Recruiting
Austin Health
Heidelberg, Australia · Recruiting
Royal North Shore Hospital
Sydney, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Australia · Recruiting
Flinders Medical Centre
Bedford Park, South Australia, Australia · Recruiting
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia · Recruiting
Medical University of Innsbruck
Innsbruck, Austria · Not yet recruiting
Showing 40 of 205 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.